ROCKVILLE, Md., Aug. 30 /PRNewswire/ -- Sequella, Inc., a clinical-stage company focused on commercialization of novel drugs for life-threatening infectious diseases, announced today the restatement of its exclusive international license agreement with the University of Maryland, Baltimore (UMB), concerning certain technology related to monitoring drug therapy compliance. The issued technology patent (U.S. 6,663,846), jointly owned by Sequella and UMB, addresses transdermal detection of a labeled pill to monitor drug compliance. Non-compliance with drug regimens contributes $290 billion in annual costs to the United States healthcare system.
"With recent technological advances, the market for drug compliance monitoring represents a tremendous opportunity for many pharmaceutical industry sectors, including those concerned with drug compliance, manufacturing, anti-counterfeiting, and clinical trial conduct," said Sequella CEO, Carol Nacy. "We are pleased to strengthen our relationship with UMB to enhance development and marketing of our assets."
Sequella's Event Marker System (EMS) for transdermal drug compliance monitoring uses a wristwatch device to detect labeled pills.
"Our exclusive license agreement with UMB is a classic win-win for both parties," said Alan Klein, Executive Vice President of Corporate Development for Sequella. "We look forward to playing a key role in the rapidly expanding marketplace for drug compliance monitoring."
"We are delighted to continue this relationship with Sequella to bring this exciting technology to market," said James L. Hughes, Vice President, Research and Development, University of Maryland.
About the Technology
The '846 patent includes "a method for monitoring drug therapy compliance, by human or animal patient, comprising contacting the patient with a transdermal detection device capable of receiving a signal from a labeled pill administered to the patient
|SOURCE Sequella, Inc.|
Copyright©2010 PR Newswire.
All rights reserved